{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:37:36Z","timestamp":1790699856354,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021069","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dadr.2026.100424","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:49:10Z","timestamp":1772984950000},"page":"100424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Relationship between extended-release buprenorphine adherence and reduced risk of return to use in patients with opioid use disorder: A retrospective claims data analysis"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-8090","authenticated-orcid":false,"given":"Michelle","family":"Jerry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-3190","authenticated-orcid":false,"given":"Divya","family":"Venkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6092-4692","authenticated-orcid":false,"given":"Courtney","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9605-936X","authenticated-orcid":false,"given":"Anh Thu","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1942-6477","authenticated-orcid":false,"given":"Maher","family":"Abdel-Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-4393","authenticated-orcid":false,"given":"William","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2026.100424_bib1","unstructured":"Ahmad, F.B., Cisewski, J.A., Rossen, L.M., Sutton, P., 2025. Provisional drug overdose death counts. National Center for Health Statistics. [Online]. Available: \u3008https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm\u3009[Accessed December 1 2025].."},{"key":"10.1016\/j.dadr.2026.100424_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/AJP.0000000000001034","article-title":"An evaluation of the effect of the OxyContin reformulation on unintentional fatal and nonfatal overdose","volume":"38","author":"Beachler","year":"2022","journal-title":"Clin. J. Pain."},{"key":"10.1016\/j.dadr.2026.100424_bib3","article-title":"Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder","volume":"21","author":"Biondi","year":"2021","journal-title":"Conte Clin. Trials Commun."},{"key":"10.1016\/j.dadr.2026.100424_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-022-00299-1","article-title":"Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community","volume":"17","author":"Biondi","year":"2022","journal-title":"Addict. Sci. Clin. Pr."},{"key":"10.1016\/j.dadr.2026.100424_bib5","doi-asserted-by":"crossref","first-page":"A188","DOI":"10.1016\/j.jval.2016.03.1375","article-title":"Relapse in opioid use disorder: implications for health care utilization and costs","volume":"19","author":"Brady","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.dadr.2026.100424_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1141093","article-title":"Barriers to opioid use disorder treatment: a comparison of self-reported information from social media with barriers found in literature","volume":"11","author":"Bremer","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.dadr.2026.100424_bib7","unstructured":"Burns, A., Hinton, E., Rudowitz, R., Mohamed, M., 2025. 10 Things to Know About Medicaid [Online]Kaiser Family Foundation (KFF) Available:\u3008https:\/\/www.kff.org\/medicaid\/10-things-to-know-about-medicaid\/\u3009[Accessed November 4 2025]."},{"key":"10.1016\/j.dadr.2026.100424_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MLR.0000000000001838","article-title":"Measurement approaches to estimating methadone continuity in opioid use disorder care","volume":"61","author":"Busch","year":"2023","journal-title":"Med. Care"},{"key":"10.1016\/j.dadr.2026.100424_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","article-title":"Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history","volume":"57","author":"Clark","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2026.100424_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9708","article-title":"Extended-release buprenorphine and its evaluation with patient-reported outcomes","volume":"4","author":"Compton","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2026.100424_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104390","article-title":"96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: extended follow-up after a single-arm trial","volume":"127","author":"Farrell","year":"2024","journal-title":"Int J. Drug Policy"},{"key":"10.1016\/j.dadr.2026.100424_bib12","article-title":"Factors associated with emergency room visits among patients with opioid use disorder: a study of buprenorphine-treated and untreated patients","volume":"16","author":"Gaiazov","year":"2025","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.dadr.2026.100424_bib13","unstructured":"Garnett, M.F., Mini\u00f1o, A.M., 2024Drug Overdose Deaths in the United States, 2003\u20132023. NCHS Data Brief No. 522, December 2024. [Online]. National Center for Health Statistics. Available:[Accessed November 4 2025].\u3008https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db522.pdf\u3009."},{"key":"10.1016\/j.dadr.2026.100424_bib14","article-title":"Comparison of social determinants of health in Medicaid vs commercial health plans","volume":"1","author":"Gibbons","year":"2023","journal-title":"Health Aff. Sch."},{"key":"10.1016\/j.dadr.2026.100424_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/HRP.0000000000000052","article-title":"Long-term course of opioid addiction","volume":"23","author":"Hser","year":"2015","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.dadr.2026.100424_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2026.1774410","article-title":"Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorder [In Press]","volume":"14","author":"Jerry","year":"2026","journal-title":"Front. Public Health"},{"key":"10.1016\/j.dadr.2026.100424_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2026.100424_bib18","article-title":"Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset","volume":"154","author":"Liao","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.dadr.2026.100424_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2026.100424_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2026.100424_bib21","doi-asserted-by":"crossref","unstructured":"Mancher, M., Leshner, A.I., 2019. Barriers to Broader Use of Medications to Treat Opioid Use Disorder [Online]National Academies Press (US)Washington (DC) Available:\u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541389\/\u3009[Accessed November 4 2025].","DOI":"10.17226\/25310"},{"key":"10.1016\/j.dadr.2026.100424_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jsat.2020.01.017","article-title":"Opioid overdose and inpatient care for substance use disorder care in Massachusetts","volume":"112","author":"Morgan","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2026.100424_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17377","article-title":"Extended-release injection vs sublingual buprenorphine for opioid use disorder with fentanyl use: a post hoc analysis of a randomized clinical trial","volume":"7","author":"Nunes","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2026.100424_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Subst. Abus. Rehabil."},{"key":"10.1016\/j.dadr.2026.100424_bib25","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/add.16652","article-title":"Prescribing of extended release buprenorphine injection for medicaid beneficiaries, 2018-2022","volume":"119","author":"Ross","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2026.100424_bib26","first-page":"e172","article-title":"Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes","volume":"23","author":"Ruetsch","year":"2017","journal-title":"Am. J. Manag Care"},{"key":"10.1016\/j.dadr.2026.100424_bib27","unstructured":"Saunders, H., Burns, A., Rudowitz, R., 2025. 5 Key facts about medicaid coverage for adults with chronic conditions [Online]Kaiser Family Foundation (KFF) Available: \u3008https:\/\/www.kff.org\/medicaid\/5-key-facts-about-medicaid-coverage-for-adults-with-chronic-conditions\/\u3009[Accessed November 4 2025]."},{"key":"10.1016\/j.dadr.2026.100424_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.dadr.2026.100424_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.37319","article-title":"Rapid vs standard induction to injectable extended-release buprenorphine: a randomized clinical trial","volume":"8","author":"Shiwach","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2026.100424_bib30","unstructured":"Substance Abuse and Mental Health Services Administration, 2021. Treatment improvement protocol (TIP) series 63: medications for opioid use disorder (HHS publication no. PEP21-02-01-002): Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration [Online]Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. Available: \u3008https:\/\/library.samhsa.gov\/sites\/default\/files\/pep21-02-01-002.pdf\u3009[Accessed November 4 2025]."},{"key":"10.1016\/j.dadr.2026.100424_bib31","unstructured":"Substance Abuse and Mental Health Services Administration, 2025. Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health (HHS Publication No. PEP25\u201107\u2011007, NSDUH Series H\u201160) [Online]Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration Available: \u3008https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt56287\/2024-nsduh-annual-national-report.pdf\u3009[Accessed November 4 2025]."},{"key":"10.1016\/j.dadr.2026.100424_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1521-0391.2011.00186.x","article-title":"Compliance with buprenorphine medication-assisted treatment and relapse to opioid use","volume":"21","author":"Tkacz","year":"2012","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.dadr.2026.100424_bib33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","article-title":"Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients","volume":"46","author":"Tkacz","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2026.100424_bib34","unstructured":"United States Centers for Disease Control and Prevention, 2025. Understanding the Opioid Overdose Epidemic [Online] Available: \u3008https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html\u3009[Accessed October 26 2025]."},{"key":"10.1016\/j.dadr.2026.100424_bib35","article-title":"Barriers to retention in medications for opioid use disorder treatment in real-world practice","volume":"160","author":"Villamil","year":"2024","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.dadr.2026.100424_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/JCI134708","article-title":"Medications for opioid use disorders: clinical and pharmacological considerations","volume":"130","author":"Volkow","year":"2020","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.dadr.2026.100424_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2026.100424_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/SAR.S440214","article-title":"Risk of relapse following discharge from non-hospital residential opioid use disorder treatment: a systematic review of studies published from 2018 to 2022","volume":"16","author":"Ware","year":"2025","journal-title":"Subst. Abus. Rehabil."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277272462600017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277272462600017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:46:07Z","timestamp":1781221567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277272462600017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S277272462600017X"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100424","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between extended-release buprenorphine adherence and reduced risk of return to use in patients with opioid use disorder: A retrospective claims data analysis","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100424"}}